Daniel De Vicente Corbeira | Board Member of FEDER
FEDER

Degree in Pharmacy. Postgraduate degree in public health. Postgraduate in Management and Strategic Planning for Non-Profit Organisations.
President of ASMD Spain
Board member of FEDER (Spanish Federation of Rare Diseases).
Board member of Eurordis (Rare Diseases Europe).
After working for more than 20 years as a community pharmacist, combining this with project development for patient organisations and the pharmaceutical industry, I finally decided to focus my education and career on this path.
Currently founder and project director of Advocacy360 Consulting. A consultancy specialising in consulting, management and strategic planning for patient organisations. I develop expert patient programmes that promote the active participation of empowered patients in decision making and relationships with all stakeholders. Patient Engagement. PROMs, PREMs and RWE/RWD projects.
Internationally, I work as a Research Liaison Officer for INPDA (International Niemann-Pick Alliance) and participate in several international working groups such as Screen4Care, DITA (Drug Information Transparency and Access), INPDR (International Niemann-Pick Disease Registry) and am a member of the CMA (Critical Medicines Alliance) of the European Commission.

Appearances:

Day 2 - Thursday 24 October @ 09:00

Keynote Panel: The Rare Disease Action Plan – where are we and how to integrate this from a European to a national level for real impact?

-What have we learnt from the last presidencies – how does the future of rare diseases look with Belgium and now Hungary’s leadership?

-How is each country executing their national action plan and are they involving their local policy makers?

Moderator: Alexandra Heumber Perry, Chief Executive Officer, Rare Diseases International

Flaminia Macchia, Head, Global Rare Disease Policy, Alexion – AstraZeneca Rare Disease

Daniel De Vicente Corbeira, Board Member of FEDER, FEDER

Avril Daly, President, Eurordis - Rare Diseases Europe

Gabriella Almberg, Head of Policy and Public Affairs, Rare Diseases, UCB

Fabienne Bartoli, Inspector General, French National Authority for Health

Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies, Sanofi

Day 2 - Thursday 24 October @ 11:10

Panel: Strategic Evidence Generation - Exploring Multiple Stakeholder Needs

The evidence-generation process for orphan therapies presents a unique set of challenges due to the rare nature of the diseases they treat. The panel will discuss the challenges and opportunities different stakeholders face when compiling and presenting evidence for orphan drugs.

Moderator: Mariam Bibi, Practice Lead, Remap Consulting